MRK Merck & Co., Inc.

Price (delayed)

$78.78

Market cap

$198.85B

P/E Ratio

19.79

Dividend/share

$2.38

EPS

$3.98

Enterprise value

$219.42B

Business Summary

Sector: Healthcare
Industry: Drug Manufacturers - General
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Highlights

The P/E is 53% lower than the 5-year quarterly average of 42.1 and 12% lower than the last 4 quarters average of 22.4
The EPS has grown by 24% YoY and by 3.6% from the previous quarter
MRK's quick ratio is down by 25% year-on-year and by 15% since the previous quarter
MRK's debt is up by 8% year-on-year and by 6% since the previous quarter

Key stats

Shares outstanding
2.52B
Market cap
$198.85B
Enterprise value
$219.42B
EBIT
$12.25B
EBITDA
$15.82B
Price to earnings (P/E)
19.79
Price to book (P/B)
7.62
Price to sales (P/S)
4.16
EV/EBIT
17.91
EV/EBITDA
13.87
Net debt/EBITDA
1.3
EV/Sales
4.56
EBITDA margin
32.9%
Gross margin
70.1%
Net margin
21.1%
Operating margin
25.5%
Return on assets
12.1%
Return on equity
38.1%
Return on invested capital
25.6%
Return on capital employed
19.9%
Return on sales
25.5%
Debt to equity
1.07
Free cash flow
$8.95B
Free cash flow per share
$3.53
Book value per share
$10.33
Revenue per share
$18.96
TBVPS
$19.34
Current ratio
1.11
Quick ratio
0.66
Working capital
$2.69B
Dividend yield
3.02%
DPS
$2.38
Payout ratio
59.8%

MRK stock price

Financial performance

The net income is up by 21% year-on-year and by 3.1% since the previous quarter
Merck & Co Inc's operating income has increased by 17% YoY and by 6% from the previous quarter
The gross profit has grown by 14% year-on-year and by 3% since the previous quarter
The revenue has grown by 12% YoY and by 2.7% from the previous quarter

Valuation

Price to earnings (P/E)
Current price to earnings (P/E):
19.79
The P/E is 53% lower than the 5-year quarterly average of 42.1 and 12% lower than the last 4 quarters average of 22.4
The EPS has grown by 24% YoY and by 3.6% from the previous quarter
Price to book (P/B)
Current price to book (P/B):
7.62
The price to book (P/B) is 41% higher than the 5-year quarterly average of 5.4 but 6% lower than the last 4 quarters average of 8.1
Merck & Co Inc's equity has decreased by 4.8% YoY
Price to sales (P/S)
Current price to sales (P/S):
4.16
The revenue has grown by 12% YoY and by 2.7% from the previous quarter
MRK's P/S is 10% below its last 4 quarters average of 4.6

Efficiency

Merck & Co Inc's ROE has increased by 35% YoY and by 4.4% from the previous quarter
The ROIC rose by 24% YoY and by 10% QoQ
The company's return on assets rose by 21% YoY and by 2.5% QoQ
The ROS has grown by 4.5% YoY and by 3.7% from the previous quarter

Dividends

DPS
$2.38
Dividend yield
3.02%
Payout ratio
59.8%

Recent dividends

Financial health

Assets vs liabilities
The total assets is 45% more than the total liabilities
MRK's quick ratio is down by 25% year-on-year and by 15% since the previous quarter
The current ratio has contracted by 19% YoY and by 11% from the previous quarter
Debt vs equity
MRK's debt is 7% greater than its equity
The debt to equity has grown by 14% YoY and by 4.9% from the previous quarter
MRK's debt is up by 8% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.